ReviewBiomedicines2022

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis.

Omar Fahmy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.